Biomarin Pharmaceutical

Health Care  |  Biotechnology
82.97 1.61 1.98%
Stock Price | Jan. 15, 2021, 4 p.m.
1 Follower
Prev. Close: 81.36
52 Week Low: 68.25
52 Week High: 131.945
PE Ratio: 18.520089
Dividend Yield: %

Company Summary

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.

Read more Read less

Recently Viewed Tickers

5 years ago

Free BioMarin Pharmaceuticals Breaks Trend

5 years ago
5 years ago
5 years ago
5 years ago